SEC Form 4 · accession 0001680739-26-000014
Travere Therapeutics, Inc. · TVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Roy D. Baynes
Director
Period of report
Jun 12, 2026
Accepted (ET)
Jun 16, 2026 · 4:42 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001438533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 12, 2026 | M | 4,500 | $21.38 | A | 46,000 | D | |
| Common Stock | Jun 12, 2026 | S | 4,500 | $50.00 | D | 41,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F2 | $21.38 | Jun 12, 2026 | M | 4,500 | D | — | May 11, 2032 | Common Stock | 4,500 | 0 | D |
Explanation of responses
- F1This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person.
- F2The stock option is fully vested and exercisable.